Stifel analyst Thomas Stephan raised the firm’s price target on Glaukos (GKOS) to $175 from $153 and keeps a Buy rating on the shares. The firm says that with the shares at all-time highs, the bar for its survey of 26 iDose-trained ophthalmologists “was lofty.” However, the checks “encouragingly met or exceeded” expectations in all key areas, the analyst tells investors in a research note. “Strong” quarterly volume expectations give Stifel greater conviction in a Q4 iDose sales figure in at least the mid-teen millions range, “representing a solid beat.” The firm notes its 2025 volume findings “were even more impressive” with a mean of 42 and median 30, suggesting 2024-trained doctors alone can drive upside to Street’s $106M 2025 iDose estimate. With moderate contribution from 2025-trained surgeons, total sales in excess of $150M is “highly achievable,” notes the firm.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos submits NDA to U.S. FDA for Epioxa to treat keratoconus
- Glaukos price target raised to $185 from $152 at Truist
- Reddit initiated, GE Vernova downgraded: Wall Street’s top analyst calls
- Glaukos upgraded to Buy from Neutral at Citi
- Buy/Sell: Wall Street’s top 10 stock calls this week
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
